Drugs / AR/101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02602184 | Nov 2015 → Jun 2017 | — | Arava Bio Tech Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR/101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02602184 ↗ |
| Route | Topical | “Topically treatment with AR/101+Standard of Care once daily for up to 21 days.” NCT02602184 ↗ |